Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Net Income | -- | -- | -34.49% | ||
| Total Depreciation and Amortization | -- | -- | -27.78% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | 491.43% | ||
| Change in Net Operating Assets | -- | -- | 65.86% | ||
| Cash from Operations | -- | -- | 22.06% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | 24.45% | ||
| Issuance of Common Stock | -- | -- | -80.86% | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -- | -- | -52.80% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -- | -- | -332.64% | ||